Life Sciences | Japan

Morrison & Foerster’s multidisciplinary Life Sciences Practice draws upon the expertise of our attorneys from a wide range of practice areas to meet the particular needs of each of our life sciences clients, large and small, around the world. We represent some of the leading participants in the biotechnology, medical technology, and pharmaceutical industries in Japan.

Our attorneys in Tokyo have extensive experience representing both Japanese and foreign life sciences companies in a wide range of matters, including corporate M&A, licensing, collaboration and other technology transactions, IP strategy issues and litigation.

Some of our recent prominent representations include:

  • Terumo Corporation in its $2.6 billion acquisition of CaridianBCT from Sweden's Gambro AB.  CaridianBCT is a leading global provider of technology, products and services in the blood banking, transfusion and cell therapy industries. The transaction is the largest acquisition ever by a Japanese company in the medical device sector.

  • Taiyo Pharmaceutical in its sale of a 57% stake to Israel’s Teva Pharmaceutical, the world's largest producer of generic drugs, in a transaction that gives Taiyo an enterprise value of $1.3 billion.

  • FUJIFILM Holdings in its $307 million acquisition of NASDAQ-listed Cellular Dynamics International, a leading developer and manufacturer of fully functioning human cells in industrial quantities based in Madison, Wisconsin.

  • Taisho Pharmaceutical, Japan’s largest over-the-counter (OTC) pharmaceutical company, in its $310 million acquisition of Bristol-Myers Squibb’s Indonesia manufacturing and distribution subsidiary, as well as brand rights for over-the-counter pharmaceutical products sold throughout Asia.

  • Ajinomoto in its $175 million acquisition of Althea Technologies, a leading U.S.-based biopharmaceutical contract development and manufacturing organization.

  • Taisho Pharmaceutical in its US$122 million acquisition of Hoepharma Holdings Sdn. Bhd. (HOE), a leading Malaysia-based pharmaceutical company.

  • Otsuka Pharmaceutical in its investment in GangaGen, a U.S. biotechnology company, focused on the discovery and development of novel therapeutics for the prevention and treatment of infectious diseases, with principal operations in Bangalore, India.

  • Taisho Pharmaceutical in its acquisition of the Flanax brand of anti-inflammatory analgesic products in the Philippines from the Roche Group.

  • Astellas in its strategic alliance with Amgen to co-develop and co-commercialize in Japan four biologics and one small molecule drug through a newly established joint venture, Amgen Astellas BioPharma KK.

  • Terumo Corporation in its sale of the DuraHeart II ventricular assist system to Thoratec Corporation for an upfront cash payment and potential future milestone payments, based on regulatory approvals and product sales, and Terumo’s related distribution arrangements with Thoratec for commercialization of DH-II.

  • Terumo Corporation in its acquisition of the remaining 78% of the outstanding shares of Mission Medical Inc. that Terumo did not already own.

  • Terumo Corporation in its acquisition of MicroVention Inc., a privately held medical device company based in Orange County, California that focuses on the development of endovascular coils and related products for the treatment of cerebral aneurysms.

  • Topcon in its acquisition of OptiMedia's glaucoma and retina businesses.

  • Omron Healthcare, a subsidiary of Omron Corp., in its proposed acquisition of all of the shares of Colin Medical from The Carlyle Group.  Colin Medical is a leading manufacturer of blood pressure and vital signs monitors for medical professionals and related equipment.

  • Astellas in its $4 billion acquisition of OSI Pharmaceuticals, the first ever unsolicited cross-border tender offer by a Japanese company.

  • Astellas in its $1 billion hostile bid to acquire CV Therapeutics.

  • Astellas in its $540 million acquisition of Agensys Inc, a Santa Monica-based biotech firm.

Chambers Asia Pacific 2019
Japan: Life Sciences (Band 2)

Chambers Global 2018
Global-wide: Life Sciences

Here is what they say about us:

“They pay good attention to detail and are very available.”
(Chambers Global 2015)

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.